Navigation Links
Alexza Pharmaceuticals' Corporate Presentation to Be Webcast at Three Upcoming Investor Conferences
Date:2/25/2013

MOUNTAIN VIEW, Calif., Feb. 25, 2013 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today its corporate presentation will be webcast live at three upcoming investor conferences.  A live webcast of each presentation may be accessed from the Investor Relations section of the Alexza Pharmaceuticals website at www.alexza.com.  The conferences and presentation times include:

  • Cowen & Company 33rd Annual Health Care Conference in Boston, MA on Tuesday, March 5, 2013 at 11:20 am ET
  • 25th Annual ROTH Conference in Dana Point, CA on Monday, March 18, 2013 at 5:30 pm ET
  • Future Leaders in the Biotech Industry Conference in New York, NY on Friday, April 5, 2013 at 10:30 am ET

A replay of each webcast will be available approximately 24 hours following the completion of the respective presentation and will be available for 14 days following the each presentation, on the Investor Relations section of the company's website. 

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals is focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions, including agitation, acute repetitive seizures and insomnia.  Alexza's products are based on the Staccato® system, a hand-held inhaler that is designed to deliver a drug aerosol to the deep lung, providing rapid systemic delivery and therapeutic onset with ease and convenience for patients. 

ADASUVE® (Staccato loxapine) is Alexza's first approved product, which was approved by the U.S. Food and Drug Administration in December 2012 and by the European Medicines Agency in February 2013.  Grupo Ferrer Internacional , S.A. is Alexza's commercial partner for ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries.  The commercial launch of ADASUVE is planned for the third quarter 2013 in the U.S. and Europe.

For more information about Alexza, the Staccato system technology or the Company's development programs, please visit www.alexza.com.  For more information about ADASUVE, please visit www.adasuve.com

ADASUVE® and Staccato® are registered trademarks of Alexza Pharmaceuticals, Inc.

Safe Harbor Statement

The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs, including the ability for Alexza and Ferrer to effectively and profitably commercialize ADASUVE, the adequacy of the Company's capital to support the Company's operations, and the Company's ability to raise additional funds and the potential terms of such potential financings. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2011 and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012
2. Alexza Receives Complete Response Letter for Adasuve™ NDA
3. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alexza Pharmaceuticals Inc.
4. Alexza Announces Reverse Stock Split in Order to Maintain NASDAQ Listing
5. Alexza Secures a $20 Million Committed Equity Financing Facility with Azimuth Opportunity, L.P.
6. Alexza Announces Management Promotions
7. Alexza Reports 2012 Second Quarter Financial Results and Provides Business Update
8. Alexza Pharmaceuticals to Present at the Stifel Nicolaus 2012 Healthcare Conference
9. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
10. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
11. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
(Date:9/22/2017)... Sept. 22, 2017  As the latest Obamacare repeal ... Bill Cassidy (R-LA) and Lindsey Graham ... the medical device industry is in an odd place. ... the 2.3% excise tax on medical device sales passed ... want covered patients, increased visits and hospital customers with ...
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical ... device is now successfully helping those with the widespread ... Fibromyalgia diagnosed Amanda in Essex, England ... and washing my hair, experiencing no sleep at all, ... painful spasm… I cannot recommend [the AVACEN 100] enough, ...
Breaking Medicine Technology:
(Date:9/25/2017)... (PRWEB) , ... September 25, 2017 , ... ... why retirement is not an option to senior, upper-level executives speaking at a ... , "A senior, high-level executive is an asset to be fully realized ...
(Date:9/25/2017)... ... September 25, 2017 , ... Leonard Bley, MD ... generation for LASIK in Manhattan with Contoura Vision, the latest WaveLight® topographic-guided laser ... available in the United States to correct nearsightedness and nearsightedness with astigmatism. This ...
(Date:9/25/2017)... (PRWEB) , ... September 25, 2017 , ... Earlypicker is ... for a one-stop shop for the hottest Korean cosmetics and fashion trends sweeping the ... a company that’s already well-known for the great offerings that allow Koreans everywhere to ...
(Date:9/25/2017)... ... 2017 , ... Dr. Edward Hebert is celebrating his 33rd anniversary ... else,” said Dr. Hebert. “I count my blessings daily for the opportunity that the ... is what I look forward to the most. The relationships I have with my ...
(Date:9/25/2017)... ... ... “Renew Refresh Restore Reward”: is a story of struggle and how trouble often ... Deborah Freeman, cofounded the Free Spirit Bible Church and currently serves as the church’s ... invited us to come over before the baby had to go back to her ...
Breaking Medicine News(10 mins):